Biokey International Inc (BKYI)

[Lone Wolf]

Watching this one for a while now. IMO, HUGE potential locked up here. Just read through their filings. From today's release:

Fourth Quarter Highlights




?


Closed a $485K order with a large regional healthcare institution that will utilize our biometric solutions to meet two factor authentication requirements for Electronically Prescribed Controlled Substances and access to Electronic Medical Records.


?


Completed a $375k follow-on order with NCR for enabling secure, biometric enabled access to their network of point of sale terminals.


?


Our Hong Kong subsidiary BIO-key HK Ltd., through our new strategic partnership with China Goldjoy, delivered an initial fingerprint biometric solution to a global payments company. The sale was valued at $244K.


?


Executed a $180K contract with a multi-factor authentication company to utilize our solutions in the healthcare and services market.


?


Collaborated with Microsoft on a 12-city tour that provided excellent visibility for our biometric solutions for Windows 10 and Office 2016. This joint marketing effort has led to a broad range of initial interest in our solutions from a range of customers, and we look forward to additional joint marketing efforts in the coming months.


?


Continued solid demand for our secure authentication solutions to support the rollout of medication management solutions provided by Aesynt, a former subsidiary of McKesson.



Special Shareholder Meeting and Pursuit of Nasdaq Capital Market Listing

As you may be aware, BIO-key is seeking shareholder approval to effect a reverse split of our common stock at some point during 2016. A special meeting has been called for later this month to approve a reverse split with share exchange ratios ranging from 1-for-4 to 1-for-12 at any time through December 31, 2016 as determined by our Board of Directors. The Board would effect a reverse split only if it were clear that such an action would likely position BIO-key common stock to meet the listing standards of the Nasdaq Capital Market. Although progress needs to be made on this front before we would pursue a listing, the Board believes a Nasdaq listing would help make BIO-key’s common stock accessible to a broader base of investors while also providing enhanced visibility for our Company and our solutions on a global basis.